盐酸阿替洛尔对比普萘洛尔治疗婴幼儿血管瘤：一项随机对照研究。
Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study.
机构信息
Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
出版信息
J Am Acad Dermatol. 2014 Jun;70(6):1045-9. doi: 10.1016/j.jaad.2014.01.905. Epub 2014 Mar 20.
BACKGROUND
Infantile hemangiomas have a dramatic response to propranolol, a nonselective beta-blocker. However, this treatment is not risk-free and many patients are excluded because of respiratory comorbidities. Atenolol is a cardioselective beta-blocker that may have fewer adverse events.
OBJECTIVE
We sought to evaluate the effectiveness of atenolol against propranolol in a noninferiority trial.
METHODS
In all, 23 patients met the inclusion criteria and were randomized to receive either atenolol or propranolol. Thirteen patients were treated with atenolol and 10 with propranolol. Follow-up was made at baseline, 2 weeks, 4 weeks, and then monthly for 6 months.
RESULTS
Patients treated with atenolol had a complete response of 53.8% and 60% with propranolol, respectively. These results were nonsignificant (P = .68). Relevant adverse events were not reported.
LIMITATIONS
The reduced number of patients could have influenced our results.
CONCLUSION
Atenolol appears to be as effective as propranolol. We did not find significant differences between these results or any adverse events.
背景
婴儿血管瘤对非选择性β受体阻滞剂普萘洛尔有显著反应。然而，这种治疗并非没有风险，许多因存在呼吸合并症的患者被排除在外。阿替洛尔是一种心脏选择性β受体阻滞剂，可能具有更少的不良反应。
目的
我们旨在通过非劣效性试验评估阿替洛尔对比普萘洛尔的疗效。
方法
共有 23 名患者符合纳入标准，并随机分为接受阿替洛尔或普萘洛尔治疗的两组。13 名患者接受阿替洛尔治疗，10 名患者接受普萘洛尔治疗。在基线、2 周、4 周时进行随访，然后每月随访 6 个月。
结果
接受阿替洛尔治疗的患者完全缓解率分别为 53.8%和 60%，但无显著差异（P =.68）。未报告相关不良反应。
局限性
患者数量减少可能影响了我们的结果。
结论
阿替洛尔似乎与普萘洛尔同样有效。我们未发现这些结果或任何不良反应之间存在显著差异。
Zotero 插件